Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis
NCT07161258Phase 2Recruiting
- Sponsor
- Roche
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of fenebrutinib in multiple sclerosis (MS), sponsored by Roche. Started Oct 2025; status: recruiting.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07161258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161258.